Exosens SA (EPA:EXENS) has revised its full-year 2026 adjusted EBITDA guidance upward to a range of €186 million to €192 million, driven by a faster-than-anticipated expansion of its European manufacturing capacity. The announcement, made on September 17, 2026, triggered a positive market reaction, with shares closing at €60.65 on Friday, up 2.97% from the prior close of €58.90.
The stock's performance was accompanied by unusually heavy trading volume, with 201,000 shares changing hands—nearly 2.9 times the recent average of 69,580 shares. This surge in activity suggests investors were responding to tangible execution progress rather than merely a quiet end-of-week session.
The updated guidance implies an adjusted EBITDA margin of 33.5% at the midpoint, up from the 32.6% implied by the previous range. This improvement indicates that the company's capacity expansion is boosting profitability at a faster rate than revenue growth. The new revenue guidance also rose, from a prior range of €520 million–€540 million to €558 million–€570 million, a midpoint increase of 6.4%.
Management attributed the upgrade to the fact that European plants operated continuously throughout August for the first time, and new equipment has been brought online. CEO Jérôme Cerisier noted that the ramp-up is meeting demand “sooner than anticipated,” underscoring the company's operational momentum.
Looking at the first half of 2026, Exosens reported revenue of €253.1 million, up 15.3% year-over-year, while adjusted EBITDA rose 18.3% to €83.6 million. The adjusted EBITDA margin expanded by 84 basis points to 33.0%. Free cash flow, however, grew only 4.7% to €31.4 million, reflecting a significant increase in capital spending, which jumped 59.6% to €23.3 million—representing 9.2% of sales, up from 6.7% in the prior-year period.
This elevated investment is a key drag on cash conversion, but the company's balance sheet provides ample room for the expansion. Net debt stood at €199.8 million as of June, with leverage easing to 1.2 times EBITDA.
The guidance update drew mixed reactions from analysts. Berenberg and All Invest Securities maintained bullish ratings, with price targets of €72 and €70, respectively, implying upside of 18.7% and 15.4% from Friday's close. Deutsche Bank, however, kept a Hold rating with a €63 target, suggesting that the current valuation already reflects much of the long-term potential.
Despite the improved operating outlook, the stock trades at a trailing price-to-earnings ratio of 101.75, according to Google Finance, which underscores the high expectations embedded in the share price. The key risk is whether the faster output can be converted into actual sales before the increased investment burden weighs on cash generation. Delays in customer deliveries or weaker defense orders could leave expanded factories underutilized.
Investors will get the next update on October 27, when Exosens reports nine-month revenue and adjusted gross margin. That release will be critical in confirming that the August production surge has indeed reached customers and translated into revenue growth.
